Intraarticular Injections of the Hip and Knee With Triamcinolone Versus Ketorolac: A Randomized Controlled Trial
Launched by SAINT ALPHONSUS REGIONAL MEDICAL CENTER · Jun 18, 2020
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Symptomatic, radiographically proven degenerative joint disease in the hip or knee
- Exclusion Criteria:
- • recent injection in the hip or knee within the previous 3 months
- • history of traumatic osteoarthritis or ligamentous reconstruction
- • chronic narcotic use
- • history of inflammatory or neuropathic arthropathy
- • pregnant and/or nursing women
- • allergy or strong reaction to study medications
About Saint Alphonsus Regional Medical Center
Saint Alphonsus Regional Medical Center is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. As a prominent sponsor, the center focuses on a diverse range of therapeutic areas, leveraging its state-of-the-art facilities and a multidisciplinary team of experts to conduct rigorous, ethically sound research. Committed to enhancing healthcare delivery, Saint Alphonsus fosters collaboration among clinicians, researchers, and the community, aiming to translate scientific discoveries into effective treatments and improved quality of care for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boise, Idaho, United States
Patients applied
Trial Officials
Kevin Jurgensmeier, BS
Principal Investigator
Student Investigator at Saint Alphonsus Regional Medical Center
Steven B Daines, MD
Study Chair
Surgeon at Saint Alphonsus Regional Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials